MedTrace Logo

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

NCT04920747 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2021-06-10

No results posted yet for this study

Summary

The purpose of this retrospective study is to evaluate the efficacy and the safety of trastuzumab + chemotherapies with or without taxanes among HER2-positive advanced gastroesophageal adenocarcinoma patients.

Conditions

Interventions

DRUG

Taxane

docetaxel or paclitaxel

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920747 on ClinicalTrials.gov